prIME Masterclass in Colorectal Cancer

prIME Masterclass in Colorectal Cancer

A Multidisciplinary Interactive Workshop

Not a member of My prIME? Join now for instant access.

This meeting is only intended for physicians from Africa, India, the Middle East, and Russia.

Meeting Overview

This one-day live meeting is specifically designed to address educational gaps regarding the treatment of patients with metastatic colorectal cancer (mCRC) and early CRC. This program will offer multimodality specialists involved in the management of CRC the opportunity to interact with leading national and international experts in the field and gain valuable insight into the most up-to-date management concepts and emerging treatment strategies for patients with CRC. In addition to didactic presentations, this program will increase audience interactivity via quiz questions (‘’brain teasers’’) and discussion of participants’ cases throughout the program.

Date and Location

Friday, 23 February 2018
08.30 – 17.00

Room: Al Noor
InterContinental Dubai – Festival City
Dubai Festival City
Dubai, United Arab Emirates

Date/Time

Date/Time

Friday, 23 February 2018
08.30 – 17.00

Location

Location

Dubai, United Arab Emirates

IME

IME

Friday, 23 February

08.30 Registration and welcome coffee
09.00 Introduction and demographics
Fathi Azribi, MD, FRCP, Claus-Henning Köhne, MD, and prIME Oncology Medical Director
09.10 Brain teasers
09.20 Keynote presentation I—Contemporary personalized management of advanced CRC in 2018
Demetris Papamichael, MBBS, MD, FRCP
09.45 Q & A
09.55 Liver-only metastases: Importance of multidisciplinary treatment approach for optimal patient outcomes (30 min)
Jose Ramos, MBBch, FCS
  • Clinical cases (20 min)
  • Multidisciplinary tumor board discussion (15 min)
11.00 Coffee break
11.25 Selecting front-line therapy for mCRC (25 min)
Claus-Henning Köhne, MD
  • Clinical cases (20 min)
  • Multidisciplinary tumor board discussion (15 min)
12.25 Lunch
14.00 Keynote presentation II—Immunotherapy in mCRC: MSI-high and beyond
Ali Shamseddine, MD, FRCP
14.25 Q & A
14.35 Continuum of care in mCRC: Second and later treatment lines (25 min)
Abdullah Al Sharm, MD
  • Clinical cases (20 min)
  • Multidisciplinary tumor board discussion (15 min)
15.35 Coffee break
15.55 What is new in adjuvant therapy for stage II and III colon cancer?
Fathi M. Azribi, MD, FRCP
16.15 Q & A
16.25 Brain teasers revisited and faculty commentary
16.40 CRC in the coming years: What can we expect?
Claus-Henning Köhne, MD
16.55 prIME Points™
Fathi M. Azribi, MD, FRCP
17.00 Adjourn

    Co-Chairs

  • Fathi M. Azribi, MD, FRCPTawam Hospital
    Al Ain, United Arab Emirates
  • Claus-Henning Köhne, MDKlinikum Oldenburg
    Oldenburg, Germany
  • Faculty

  • Abdullah Al Sharm, MDKing Fahad Medical City
    Riyadh, Saudi Arabia
  • Demetris Papamichael, MBBS, MD, FRCPCyprus Oncology Centre
    Nicosia, Cyprus
  • Jose Ramos, MBBch, FCS Wits University Donald Gordon Medical Centre
    Johannesburg, South Africa
  • Ali Shamseddine, MD, FRCPAmerican University of Beirut Medical Center
    Beirut, Lebanon

This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical and radiation oncologists, and other healthcare professionals from Africa, India, the Middle East, and Russia who are involved in the management of CRC.

Upon completion of this educational activity, participants should be able to:

  • Explain state-of-the-art management of early and mCRC, and evaluate current and emerging biomarkers to guide personalized therapy
  • Identify multidisciplinary treatment approaches that may lead to optimal treatment outcomes for patients with liver-only metastases
  • Select optimal front-line treatment for patients with mCRC and assess sequencing strategies beyond disease progression
  • Evaluate treatment options for metastatic BRAF-mutant mCRC
  • Describe emerging agents in mCRC, including immunotherapy-based combinations

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.